💊 VKTX Down Despite Positive Obesity Drug Data; GILD Hits 8.5-Year High Ahead of Earnings; MDGL Gains on Novo Nordisk Data Boost | Biotech Sector Insights
(IBB) has seen a decrease of 0.1% since Friday. In the previous week, from October 28 to November 1, the ETF recorded a gain of 0.90%, reaching a price of 142.78. Key contributors to this performance included GILD, ILMN, APLS, HALO, and MTD, each registering positive returns.
Welcome to the MarketReader Minute.
Below are AI-generated insights on moves in the health care/biotechnology sector, powered by MarketReader technology.
Monday, November 4
IBB [-0.1%]
iShares Biotechnology ETF (IBB)
The iShares Biotechnology ETF (IBB) has seen a decrease of 0.1% since Friday. In the previous week, from October 28 to November 1, the ETF recorded a gain of 0.90%, reaching a price of 142.78. Key contributors to this performance included GILD, ILMN, APLS, HALO, and MTD, each registering positive returns. Notably, Piper Sandler maintained a Neutral rating on Halozyme Therapeutics while raising its price target to 52. Additionally, H.C. Wainwright analyst Mitchell Kapoor raised the price target for Halozyme to 68 with a Buy rating. Mettler-Toledo International Inc. is scheduled to present at upcoming investor conferences to highlight its operational strengths and strategic initiatives.